CMA says MSD operated anti-competitive Remicade scheme
The UK Competition and Markets Authority (CMA) has provisionally decided that Merck Sharp & Dohme operated an anti-competitive discount scheme for its drug Remicade (infliximab).
Remicade is a biological treatment for patients with gastroenterology and rheumatology conditions.
In a statement released yesterday, the CMA said it had provisionally found that Merck broke competition law.
CMA said that Merck did this through a discount scheme for Remicade that was “likely to restrict competition” for biosimilar versions of infliximab.
It added: “At this stage of the CMA’s investigation, these findings are provisional and no conclusion should be drawn that there has in fact been any breach of competition law.
“The CMA will carefully consider any representations by the company under investigation before determining whether the law has been infringed.”
The CMA started this investigation in December 2015.
Today's stories
University of Maryland patent immune to IPR: PTAB
WIPO reveals new plan to fight tropical diseases
Federal Circuit rules in Mylan’s favour
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
